Sabinsa Corp.’s Curcumin C3 Complex could offer a major inflammatory-reduction benefit to traumatic brain injury patients, according to results of a study conducted by researchers from medical schools in Iran.
Among a panel of 62 patients in the double-blind, placebo-controlled and randomized study, daily use of a supplement with 500 mg C3 Complex and 5 mg of Sabinsa’s bioavailability enhancer BioPerine, which promotes absorption, showed a statistically significant decrease
Calling Out Exaggerated Amla Claims In Vitamin C
Sabinsa says competitors are attempting to cash in on growing demand for vitamin C by inaccurately claiming to offer high concentrations of the nutrient derived from amla extract.
The firm analyzed products claiming as much as 25% concentration to isolate vitamin C in the formulations from amla extract, also known as Indian gooseberry, and to trace the origin of the nutrient to fermentation rather than to amla, it said in a 17 June release.
Sabinsa says its experience manufacturing its Saberry amla extract brand with a standardized amount of 10% beta-glucogallin, an alternative antioxidant to ascorbic acid, drew its attention to competitors’ claims. It argues that suppliers should disclose when they blend fermentation-derived vitamin C with amla extract and claim 25% concentration.
The firm also argues it is not economically feasible to isolate and extract vitamin C up to 25% from the raw material alma extract, but other ingredient providers are claiming they are. It says studies have shown that amla isn’t a valid biomarker or a source of high amounts of vitamin C because it doesn’t contain ascorbic acid in consistent amounts and often only in trace quantities
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?